2024
Systemic anti-cancer treatment and healthcare utilization at end of life: A SEER Medicare analysis.
Adelson K, Canavan M, Niu J, Zhao H, Nortje N, Xiang J, Giordano S, Cheng L. Systemic anti-cancer treatment and healthcare utilization at end of life: A SEER Medicare analysis. Journal Of Clinical Oncology 2024, 20: 276-276. DOI: 10.1200/op.2024.20.10_suppl.276.Peer-Reviewed Original ResearchEnd-of-lifeSystemic anticancer therapyDay of deathIntensive care unit useIntensive care unitHealthcare utilizationEmergency departmentCombined chemo-immunotherapyEnd-of-life chemotherapy useAssociated with healthcare utilizationImmunotherapy useChemo-immunotherapyIncreased healthcare useEnd of lifeAdverse quality of lifeAssociated with higher EDCare unitQuality of lifeSystemic anti-cancer treatmentHospice useDay hospiceHospice enrollmentSEER-Medicare databaseUse of chemotherapyHealthcare use
2020
The association between initial chemotherapy treatment timing, intensity, and end-of-life (EOL) care trajectory among older adults with advanced stage lung cancer (aLC).
Presley C, Shahzad H, Canavan M, Prsic E, Saphire M, Wang S, Davidoff A. The association between initial chemotherapy treatment timing, intensity, and end-of-life (EOL) care trajectory among older adults with advanced stage lung cancer (aLC). Journal Of Clinical Oncology 2020, 38: e24009-e24009. DOI: 10.1200/jco.2020.38.15_suppl.e24009.Peer-Reviewed Original ResearchAdvanced-stage lung cancerDoublet chemotherapyEOL groupOlder adultsIntensity groupInitial chemotherapy regimenInitial chemotherapy treatmentPlatinum-based doubletsPlatinum-doublet chemotherapyFirst-line therapyUse of chemotherapyMajority of patientsEOL care preferencesStage lung cancerMain outcome measuresNon-Hispanic whitesMedicare registryChemotherapy regimenLine therapyCisplatin chemotherapyLung cancerChemotherapy treatmentAge 66Outcome measuresCare trajectories